Association between the BCR-ABL gene transcripts and the laboratory hematological profile

• Autor(a) principal: Oliveira, Marcelo Braga de
• Data de Publicação: 2022
• Outros Autores: Maneschy, Carolina de Alcântara, Castro, Jairo Augusto Américo de, Barile, Katarine Antonia dos Santos, Palmeira, Maurício Koury, Amaral, Carlos Eduardo de Melo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista Ciências em Saúde
• DOI: 10.21876/rcshci.v12i3.1281
• Texto Completo: https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1281
• topic: Chronic Myeloid Leukemia; BCR ABL gene; Hematology; Leucemia Mieloide Crônica; gene BCR ABL; Hematologia

Objective: This study describes the hematological parameters associated with the BCR-ABL gene transcripts in patients with chronic myeloid leukemia (CML). Methods: We reviewed the results of 100 detectable patients for one of the BCR-ABL gene transcripts. The eligibility criteria were based on the presence of one of the leukemic transcripts (b2a2, b3a2, and b2a2/b3a2) and complete epidemiological and hematological data. The data were obtained from the LabMaster computerized system. The Kruskal-Wallis test was used to compare the medians of the quantitative variables between the transcripts of the BCR-ABL gene and the chi-square test to compare the qualitative ones, adopting the p-value with a level of significance less than or equal to 0.05. Results: Forty-five patients (45%) presented the b2a2 transcript, 24 (24%) the b3a2 transcript and 31 (31%) a b2a2/b3a2 coexpression. Individuals who expressed the b3a2 transcript had higher leukocyte counts and platelet levels, but we found no differences compared with individuals who expressed the other transcript. Conclusion: In this study, the BCR-ABL gene transcripts did not influence the hematological parameters of patients with CML.